Good Start Genetics, a Cambridge, Mass.-based molecular diagnostics company, has raised $14m in Series B financing.
The round was led by existing investors OrbiMed Advisors, Safeguard Scientifics, and SV Life Sciences.
The company intends to use the funding to expand the commercial efforts for its pre-conception carrier screening tests, and to conduct R&D initiatives around its proprietary technology platform for future applications.
Led by President and CEO Don Hardison, Good Start Genetics leverages the power of innovative sequencing and other technologies to provide tests for all ACOG and ACMG recommended disorders.
FinSMEs
02/04/2012